Sorafenib in patients with refractory or recurrent multiple myeloma
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction and angiogenic pathways. It is approved for the tre...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 March 2013
|
| In: |
Hematological oncology
Year: 2013, Volume: 31, Issue: 4, Pages: 197-200 |
| ISSN: | 1099-1069 |
| DOI: | 10.1002/hon.2043 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/hon.2043 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2043 
|
| Author Notes: | Anna Yordanova, Dirk Hose, Kai Neben, Mathias Witzens-Harig, Ines Gütgemann, Marc-Steffen Raab, Thomas Moehler, Hartmut Goldschmidt and Ingo G.H. Schmidt-Wolf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1764357361 | ||
| 003 | DE-627 | ||
| 005 | 20230426140758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210726s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.2043 |2 doi | |
| 035 | |a (DE-627)1764357361 | ||
| 035 | |a (DE-599)KXP1764357361 | ||
| 035 | |a (OCoLC)1341419874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Yordanova, Anna |e VerfasserIn |0 (DE-588)1130357023 |0 (DE-627)884653412 |0 (DE-576)486768813 |4 aut | |
| 245 | 1 | 0 | |a Sorafenib in patients with refractory or recurrent multiple myeloma |c Anna Yordanova, Dirk Hose, Kai Neben, Mathias Witzens-Harig, Ines Gütgemann, Marc-Steffen Raab, Thomas Moehler, Hartmut Goldschmidt and Ingo G.H. Schmidt-Wolf |
| 264 | 1 | |c 15 March 2013 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.07.2021 | ||
| 520 | |a Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction and angiogenic pathways. It is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The objectives of this prospective phase II trial were to assess the activity and tolerability of sorafenib in patients with recurrent or refractory myeloma. In total, 11 patients were enrolled. Patients received 2 × 200 mg of sorafenib orally twice daily until completing 13 full cycles or disease progression. Of the side effects, 8.8% grade 3 and 1.1% grade 4 occurred. Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24.4 months and 6.9 month, respectively. Further clinical investigations are recommended to investigate sorafenib single agent activity in myeloma subgroups with ras-/BRAF-/vascular endothelial growth factor receptor pathway activation and combination therapy approaches. | ||
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a phase II clinical trial | |
| 650 | 4 | |a recurrent | |
| 650 | 4 | |a refractory | |
| 650 | 4 | |a sorafenib | |
| 700 | 1 | |a Hose, Dirk |d 1969- |e VerfasserIn |0 (DE-588)139824995 |0 (DE-627)613790308 |0 (DE-576)313431698 |4 aut | |
| 700 | 1 | |a Neben, Kai |d 1969- |e VerfasserIn |0 (DE-588)120842181 |0 (DE-627)080920470 |0 (DE-576)292411774 |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d New York, NY [u.a.] : Wiley Interscience, 1983 |g 31(2013), 4, Seite 197-200 |h Online-Ressource |w (DE-627)320412040 |w (DE-600)2001443-0 |w (DE-576)114617414 |x 1099-1069 |7 nnas |a Sorafenib in patients with refractory or recurrent multiple myeloma |
| 773 | 1 | 8 | |g volume:31 |g year:2013 |g number:4 |g pages:197-200 |g extent:4 |a Sorafenib in patients with refractory or recurrent multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hon.2043 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2043 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210726 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 120842181 |a Neben, Kai |m 120842181:Neben, Kai |d 50000 |e 50000PN120842181 |k 0/50000/ |p 3 | ||
| 998 | |g 139824995 |a Hose, Dirk |m 139824995:Hose, Dirk |d 910000 |d 910100 |e 910000PH139824995 |e 910100PH139824995 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1764357361 |e 3957607604 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Anna","role":"aut","display":"Yordanova, Anna","family":"Yordanova"},{"given":"Dirk","role":"aut","display":"Hose, Dirk","family":"Hose"},{"family":"Neben","display":"Neben, Kai","role":"aut","given":"Kai"},{"role":"aut","given":"Mathias","family":"Witzens-Harig","display":"Witzens-Harig, Mathias"},{"display":"Raab, Marc-Steffen","family":"Raab","role":"aut","given":"Marc-Steffen"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 26.07.2021"],"origin":[{"dateIssuedDisp":"15 March 2013","dateIssuedKey":"2013"}],"title":[{"title_sort":"Sorafenib in patients with refractory or recurrent multiple myeloma","title":"Sorafenib in patients with refractory or recurrent multiple myeloma"}],"id":{"eki":["1764357361"],"doi":["10.1002/hon.2043"]},"name":{"displayForm":["Anna Yordanova, Dirk Hose, Kai Neben, Mathias Witzens-Harig, Ines Gütgemann, Marc-Steffen Raab, Thomas Moehler, Hartmut Goldschmidt and Ingo G.H. Schmidt-Wolf"]},"physDesc":[{"extent":"4 S."}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Sorafenib in patients with refractory or recurrent multiple myelomaHematological oncology","note":["Gesehen am 27.02.08"],"origin":[{"publisherPlace":"New York, NY [u.a.]","dateIssuedKey":"1983","publisher":"Wiley Interscience","dateIssuedDisp":"1983-"}],"pubHistory":["1.1983 -"],"title":[{"title":"Hematological oncology","title_sort":"Hematological oncology"}],"id":{"eki":["320412040"],"issn":["1099-1069"],"zdb":["2001443-0"],"doi":["10.1002/(ISSN)1099-1069"]},"recId":"320412040","physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"31(2013), 4, Seite 197-200","issue":"4","pages":"197-200","year":"2013","volume":"31","extent":"4"},"language":["eng"]}],"recId":"1764357361"} | ||
| SRT | |a YORDANOVAASORAFENIBI1520 | ||